Previous 10 | Next 10 |
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it will host a Key Opinion Leader (KOL) Symposium on the GAS6-AXL signaling pathway and the Compa...
HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of two poster abstracts at the upcoming American Society of Clinical Oncology (ASCO...
Referring to the most up-to-date market data as of Apr. 11, Cantor Fitzgerald has listed the biotech companies with the most notable changes in the short interest. The nano-cap commercial-stage pharma company, Clarus Therapeutics (CRXT) dominates the list with over ten times increase in short...
Aravive Inc. (NASDAQ:ARAV) traded at a new 52-week high today of $29.60. Approximately 17.2 million shares have changed hands today, as compared to an average 30-day volume of 55,000 shares. In the past 52 weeks, shares of Aravive Inc. have traded between the current low of $1.28 and a h...
HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq r...
Aravive press release (NASDAQ:ARAV): Q4 GAAP EPS of -$0.62 misses by $0.02. Revenue of $0.99M (-82.6% Y/Y) misses by $0.52M. As of December 31, 2021, cash and cash equivalents were $59.4 million, compared to $60.5 million as of December 31, 2020. For further details see: Aravive GAAP EP...
Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q’22; on track to report updated data in 2Q’22 Dosed first patient in Phase 2 trial of batiraxcept in ccRCC in January 2022; on track to ...
Aravive (NASDAQ:ARAV) has announced a ~$10M registered direct offering priced at-the-market under Nasdaq rules. The oncology firm entered into definitive agreements with a single healthcare-focused institutional investor and Eshelman Ventures to offer 4.85M shares of its common stock and warr...
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional invest...
Aravive (NASDAQ:ARAV) has appointed industry veteran, Scott Dove, Ph.D., as Chief Operating Officer. Most recently, he served as Senior Vice President and General Manager at PPD, where he provided strategic direction and oversight of PPD’s Early Development Services business unit....
News, Short Squeeze, Breakout and More Instantly...
Amerityre Corp (AMTY) is expected to report for Q3 2024 CURO Group Holdings Corp. (CUROQ) is expected to report for Q1 2024 China Health Industries Holdings Inc (CHHE) is expected to report for Q3 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Anterix In...
Blue Ridge Real Estate Co. (BRRE) is expected to report for Q2 2024 Aravive Inc. (ARAV) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Golden Matrix Group Inc. (GMGI) is expected to report for Q2 2024 Bluejay Diagnostics Inc. (BJDX) is exp...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...